AR and prostate cancer: BAY 1024767 is a novel competitive AR antagonist that exhibits strong activity against AR wild-type and mutated forms found in therapy-resistant patients, keeps antagonistic activity with increased androgen stimulation and in prostate cancer models with elevated AR protein levels.